We have some good news to share. This week the U.S. Food and Drug Administration (FDA) granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). This is the first drug fully approved for glioblastoma in nearly two decades.
ABC2 is proud of the pivotal role we’ve played in the development of this therapy that is providing improved quality of life for glioblastoma patients. In 2003, we initiated a revolutionary partnership with the biotechnology company Genentech. ABC2’s goal in this partnership was to move Avastin rapidly into clinical testing for glioblastoma—by directly funding the trials themselves. This unprecedented “buying down” of Genentech’s financial risk was a marked success: after demonstrating positive results in two clinical trials, Avastin received accelerated FDA approval in 2009 for the treatment of recurrent glioblastoma, becoming the first drug approved for glioblastoma in over a decade.
Since Avastin’s accelerated approval, ABC2 has remained actively engaged with its journey toward the clinic. When late-stage trials to confirm the drug’s safety and effectiveness produced conflicting results, ABC2 stepped in to advocate for FDA review of the full results from the trials in question.
Brain cancer breakthroughs don't follow conventional wisdom. Neither do we. Since our founding, we’ve helped bring 30 new treatments into the clinic for patients. The approval of Avastin is a big step forward, but ABC2 is committed to push the limits of science and technology much further. Today, we are working on genomic profiling, gene therapy, immunotherapy and novel clinical trial projects that we believe will significantly improve a patient’s quality of life and survival.
Max Wallace, CEO of ABC2